OK, I’m not usually a big fan of end-of-the-year lists. But given that Xconomy Seattle has been up and running for almost exactly six months (since June 16), Luke and I thought it would be fun and informative to share our site’s top 10 most-read stories so far—and why we think they were important or special.
The list is an interesting mix of stories that captures the spirit of what we’re doing here at Xconomy, and it also gives a pretty balanced retrospective on the events of the past half-year. The stories represent our commitment to cover all sorts of innovation in the Northwest, spanning technology, life sciences, breaking news (both good and bad), and in-depth features and analysis.
So, without further ado, here are the 10 most-read Xconomy Seattle stories of the past half-year:
This piece covered how Microsoft relates to the startup community, through a review of the first 30 days of its BizSpark program.
The untold story of how Tysabri, the most effective multiple sclerosis drug on the market, was invented in a lab right here in Seattle.
Readers were excited to hear about one of the bigger venture financing deals of the year in Seattle, led by a team of superstars in immunology.
This was bad news based on a layoff filing from Washington State’s Employment Security Department. A global law firm with a large Seattle office, known for its work in the tech and life sciences community, has left the scene.
The story of a 13-year quest: how the persistence of a Seattle scientist at Amgen may pay off in the coming year, through a new drug for bone loss called denosumab.
An exclusive, in-depth interview with Nathan Myhrvold of Intellectual Ventures. The former Microsoft chief technology officer and founder of Microsoft Research covered everything from ping-pong with … Next Page »